Holen Sie sich die Stockscreener-App
2.7069
1.28%
-0.0331
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt FBIO?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$2.74
Offen:
$2.8
24-Stunden-Volumen:
402.95K
Relative Volume:
0.60
Marktkapitalisierung:
$89.86M
Einnahmen:
$66.16M
Nettoeinkommen (Verlust:
$128.94M
KGV:
0.8506
EPS:
3.1823
Netto-Cashflow:
$152.08M
1W Leistung:
+6.92%
1M Leistung:
+16.09%
6M Leistung:
-1.99%
1J Leistung:
+51.97%
1-Tages-Spanne:
$2.665
$2.835
1-Wochen-Bereich:
$2.565
$2.86
52-Wochen-Spanne:
$1.70
$4.53
Fortress Biotech Inc Stock (FBIO) Company Profile
Firmenname
Fortress Biotech Inc
Sektor
Branche
Telefon
781-652-4500
Adresse
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Compare FBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FBIO
Fortress Biotech Inc
|
2.705 | 91.02M | 66.16M | 128.94M | 152.08M | 3.1823 |
VRTX
Vertex Pharmaceuticals Inc
|
436.73 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.59 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
805.44 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.70 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.32 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-15 | Fortgesetzt | ROTH MKM | Buy |
| 2022-08-04 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2020-10-02 | Eingeleitet | The Benchmark Company | Buy |
| 2019-12-18 | Eingeleitet | B. Riley FBR | Buy |
| 2018-02-28 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-07-11 | Eingeleitet | Rodman & Renshaw | Buy |
| 2017-03-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-10-03 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Fortress Biotech Inc Aktie (FBIO) Neueste Nachrichten
FBIO Q4 2025 Earnings: Deep EPS Miss Highlights Challenges for Pre-Revenue BiotechTrough Earnings Signal - Newser
(FBIOP) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Fortress Biotech Preferred Stock (FBIOP) Q4 2025 Earnings: EPS Misses Estimates by Over 108%Community Sell Signals - Newser
Fortress Biotech (FBIO) Gains 1.62% as Shares Approach Key Resistance at $2.97Stock Analysis - Newser
Fortress Biotech Inc. (FBIO) Moves Higher as Buyers Defend Key Support LevelChaikin Flow - Newser
FBIOP Stock Price, Quote & Chart | FORTRESS BIOTECH INCFBIO 9 3/8 PERP (NASDAQ:FBIOP) - ChartMill
Fortress Biotech (FBIO) Q4 2025 Results Miss Estimates — EPS $-0.01 vs $0.11Consensus Beat Rate - Newser
Fortress Biotech (FBIO) Q4 2025 Earnings: Miss Sparks ConcernGAAP Earnings Report - Newser
Fortress Biotech (FBIO) Q4 2025 Miss: What Went WrongGuidance Downgrade Alert - Newser
Journey Medical CEO to join online talk at A.G.P. health event - Stock Titan
Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference - Sahm
A. G. P. Maintains Fortress Biotech(FBIO.US) With Buy Rating, Raises Target Price to $5 - Moomoo
Why Fortress Biotech (FBIO) Just Surged +5.81% — Key Levels Ahead 2026-05-18Factor Timing - Newser
FBIO Stock Surges 12% Pre-Market After It Wins FDA Approval For Rare Pediatric Menkes Disease - Stocktwits
Number of shareholders of Fortress Biotech, Inc. – NASDAQ:FBIO - TradingView
Fortress Biotech, Inc.9.375% Series A Cumulative Redeemable Perpetual Preferred Stock - TradingView
Fortress Biotech stock (US32015L1035): FDA setback hits Menkes drug while investors eye next catalys - AD HOC NEWS
Fortress Biotech Inc at Planet MicroCap Showcase Virtual Investor Conference 2020 Transcript - GuruFocus
Highbridge (FBIO) reports 2.73M warrant-backed shares, 7.8% stake - Stock Titan
FBIOP | Fortress Biotech, Inc. 9.375% Insider Trading - Quiver Quantitative
Fortress Biotech (FBIO) Q1: EPS $2.82 Beats Est. -$0.22; Revenue - GuruFocus
Fortress Biotech Q1 2026 Earnings Call Transcript - MarketBeat
Fortress Biotech: Q1 Earnings Snapshot - marketscreener.com
Fortress Biotech, Inc. 1Q 2026: Revenue $15.92M, Net income $110.37M, EPS $2.82— 10-Q Summary - TradingView
Fortress Biotech posts $108.4M net income in Q1 2026, revenue $16.0M - TradingView
Priority review voucher sale drives Fortress Biotech (FBIO) Q1 2026 profit and cash surge - Stock Titan
Fortress Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Fortress Biotech (NASDAQ: FBIO) turns Q1 2026 profit after $205M PRV sale - Stock Titan
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - Yahoo Finance
Fortress Biotech stock (US32015L1035): Q1 earnings miss on revenue, but EMROSI shows momentum - AD HOC NEWS
Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - marketscreener.com
(FBIOP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
TradingKey - TradingKey
MSN Money - MSN
Fortress Biotech Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
Earnings Preview: FBIO to Report Financial Results Post-market on May 13 - Moomoo
Journey Medical to discuss quarterly results and corporate update May 13 - Stock Titan
Mustang Bio (NASDAQ: MBIO) reports Q1 loss, limited cash and Nasdaq bid-price risk - Stock Titan
Fortress Biotech CEO to speak at royalty company virtual conference - Stock Titan
Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference - marketscreener.com
(FBIOP) Risk Channels and Responsive Allocation - Stock Traders Daily
FBIO Stock Price, Quote & Chart | FORTRESS BIOTECH INC (NASDAQ:FBIO) - ChartMill
Fortress Biotech to Receive $205M as Cyprium Agrees Sale of Rare Pediatric Disease Priority Review Voucher - MSN
Executive pay, ownership and auditor up for vote at Fortress Biotech (NASDAQ: FBIO) - Stock Titan
What Is Driving Performance | Fortress Biotech posts 108.9% negative EPS miss vs estimatesWall Street Picks - Newser
Why Is Fortress Biotech Stock Falling Today? - MSN
Fortress Bio gains on FDA approval of copper replacement therapy - MSN
Fortress (FBIOP) Market Conditions | Fortress Biotech pref posts 108.9% steep EPS missInvestor Call - Cổng thông tin điện tử tỉnh Lào Cai
Fortress (FBIOP) Investment Case | Q4 2025: Earnings Fall ShortCrowd Trend Signals - Cổng thông tin điện tử tỉnh Tây Ninh
Finanzdaten der Fortress Biotech Inc-Aktie (FBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):